Toll Free : 1-800-489-3075

Global Cancer Antibody Drug Conjugates Industry 2017 Market Research Report

Choose License Type
Published by:

QYResearch

Category:

Pharmaceuticals & Healthcare

Published On:

September 2017

No of pages:

113

Report Format:

Electronic (PDF)

In this report, the global Cancer Antibody Drug Conjugates market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cancer Antibody Drug Conjugates in these regions, from 2012 to 2022 (forecast), covering

• North America
• Europe
• China
• Japan
• Southeast Asia
• India

Global Cancer Antibody Drug Conjugates market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

• Novartis
• Merck
• Roche
• AbbVie
• UCB
• Bristol-Myers Squibb
• Stem CentRx
• Biogen Idec
• Nordic Nanovector
• Millennium
• Biotest AG
• PDL BioPharma
• Progenics Pharmaceuticals
• Seattle Genetics
• Viventia Biotechnologies
• AbGenomics Corporation
• Helix BioPharma

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• First & Second Generation ADCs
• Third Generation ADCs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Cancer Antibody Drug Conjugates for each application, including

• Hospitals
• Clinics
• Other

If you have any special requirements, please let us know and we will offer you the report as you want.